Understanding Linkers and Payloads in Breast Cancer Treatment

Join Dr. VK Gadi and Dr. Anne O’Dea as they discuss advances in HER2-positive breast cancer treatment using antibody-drug conjugates (ADCs) such T-DXd and T-DM1 and hormone-positive and triple-negative breast cancer with sacituzumab govitecan. Dr. O’Dea also drills down upon how current ADCs differ from chemotherapy and amongst themselves.

A main point is Sacituzumab govitecan, which targets Trop-2, has demonstrated notable survival advantages in the ASCENT and TROPiCS trials for triple-negative and hormone-positive HER2-negative breast cancers, respectively. These trials demonstrate sacituzumab govitecan is better than chemotherapy for quality of life, making it a good option for all breast cancer subtypes. To improve metastatic breast cancer outcomes, ADC development must continue.